BREAKING NEWS

Roche breast cancer drug extends overall survival

By REUTERS

DECEMBER 8, 2012 12:05

ZURICH - Swiss pharma group Roche's drug Perjeta significantly extended the lives of women with an aggressive and incurable form of breast cancer compared to a placebo, according to new data from a late-stage study presented on Saturday.

The detailed data presented at the San Antonio Breast Cancer Symposium found that the risk of death was reduced by 34 percent in women treated with a combination treatment of the drugs Perjeta and Herceptin plus chemotherapy compared to women treated with Herceptin, chemotherapy and a placebo, Roche said.

Roche is hoping that the Perjeta combination will become the standard treatment for women with a form of cancer known as HER2-positive, which makes up about a quarter of all breast cancers and has no cure.

White House: Diplomatic solution in Middle East 'urgent"

By REUTERS

09/19/2024 10:42 PM

Explosives implanted in devices before they arrived in Lebanon – report

By REUTERS

09/19/2024 10:36 PM

Delta to pause flights between New York and Tel Aviv

By REUTERS

09/19/2024 10:23 PM

IDF to conduct large-scale training in northern Israel over weekend

By JERUSALEM POST STAFF

09/19/2024 09:40 PM